According to a recent LinkedIn post from Isomorphic Labs, Chief Research Officer Sarah Skerratt is scheduled to participate in a panel at the Revolution 2026 event in Washington, D.C. The post indicates she will discuss current applications of AI in drug discovery, potential future developments, and the importance of responsible innovation in this domain.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also highlights the company’s internal drug design engine, referred to as IsoDDE, which is described as enabling exploration of new areas of chemistry and biology that have been difficult to access using traditional methods. This tool is portrayed as accelerating the progression from early research toward potential new medicines, suggesting ongoing investment in proprietary AI platforms that could enhance Isomorphic Labs’ competitiveness and partnership appeal in the biopharmaceutical R&D market.